Journal article

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

JK Mooi, P Wirapati, R Asher, CK Lee, P Savas, TJ Price, A Townsend, J Hardingham, D Buchanan, D Williams, S Tejpar, JM Mariadason, NC Tebbutt

Annals of Oncology | OXFORD UNIV PRESS | Published : 2018

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia


Awarded by NHMRC Senior Research Fellowship


Funding Acknowledgements

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (1048088); Ludwig Cancer Research; the Operational Infrastructure Support Program, Victorian Government, Australia; NHMRC Senior Research Fellowship (1046092) to JMM; BEAT Cancer Council South Australia Grant to AT and PhD scholarship from Perpetual Philanthropic Grants (Reginald Marsden charitable trust) to JKM. Gene expression profiling was provided and carried out by Almac Diagnostics, Craigavon, UK.